MiniMed Group (NASDAQ:MMED) Upgraded to Strong-Buy at Benchmark

MiniMed Group (NASDAQ:MMED) was upgraded by equities researchers at Benchmark to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Other research analysts have also issued reports about the company. Mizuho initiated coverage on MiniMed Group in a report on Tuesday, March 31st. They issued an “outperform” rating and a $21.00 price objective on the stock. William Blair assumed coverage on MiniMed Group in a research report on Tuesday, March 31st. They set an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft began coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $20.00 price objective for the company. Zacks Research upgraded MiniMed Group to a “hold” rating in a research report on Thursday, April 9th. Finally, Morgan Stanley started coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $19.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

MiniMed Group Trading Up 6.5%

MMED stock opened at $11.89 on Monday. MiniMed Group has a 1-year low of $11.10 and a 1-year high of $20.48. The business’s 50 day simple moving average is $14.42.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.